Journal Article Summary
The article investigates the effects of tirzepatide, a new medication that acts on both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, on gastric emptying (GE). This topic is significant because gastric emptying plays a crucial role in managing blood sugar levels, particularly in individuals with type 2 diabetes (T2DM). Understanding how tirzepatide influences GE can provide insights into its potential benefits for glycemic control and weight management in patients with diabetes.
In the study, researchers conducted both animal and human trials to assess the impact of tirzepatide on GE compared to other GLP-1 receptor agonists, such as semaglutide and dulaglutide. In mice, tirzepatide was found to delay gastric emptying similarly to semaglutide, but this effect diminished after two weeks of treatment. In human participants, those with and without T2DM experienced a delay in GE after a single dose of tirzepatide, although this effect lessened with repeated doses. Notably, participants with T2DM still showed some delay in GE after multiple doses, indicating a potential residual effect.
The study has limitations, including a short duration of only four weeks, which may not fully capture the long-term effects of tirzepatide on gastric emptying. Additionally, the methods used to measure GE may not be the most precise available. Patients should discuss the findings and any concerns about tirzepatide with their healthcare providers, particularly regarding its use for managing diabetes and its effects on gastric emptying and overall health.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Urva Shweta, Coskun Tamer, Loghin Corina, Cui Xuewei, Beebe Emily, O'Farrell Libbey, Briere Daniel A., Benson Charles, et al.. The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists. Diabetes, Obesity & Metabolism 2020. DOI: 10.1111/dom.14110. PMID: 32519795. PMCID: PMC7539915.
Featured Pill Pals Product
Tirzepatide --- 72 mg / 4 ml --- 4 ml vial --- Weight Loss Glucagon-Like Peptide-1 (GLP-1)
Tirzepatide --- 72 mg / 4 ml --- 4 ml vial --- Weight Loss Glucagon-Like Peptide-1 (GLP-1) is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
